About this document
Phase III Trial of Nonpegylated Liposomal Doxorubi by maryjilliansampag10 is a document available to read on EtoBox.
This phase III trial compared the efficacy and safety of nonpegylated liposomal doxorubicin (NPLD) combined with trastuzumab and paclitaxel (MTP) versus trastuzumab and paclitaxel alone (TP) in patients with HER2-positive metastatic breast cancer. The trial found no significant improvement in progression-free survival (PFS) or overall survival (OS) with MTP compared to TP, although exploratory analysis suggested potential benefits in patients with estrogen receptor (ER)- and progesterone receptor (PR)-negat
- Author
- maryjilliansampag10
- Language
- EN